News

Pulmonary arterial hypertension (PAH) is one of the most serious health problems associated with systemic sclerosis (SSc). Researchers have found that specific biomarkers, known as autoantibodies, are associated with an increased risk in the development of PAH in people with SSc. It is not yet known, however, whether or not these…

Cytori Therapeutics, Inc., a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions, recently announced the beginning of its U.S. phase III/pivotal STAR clinical trial in the United States that will assess the efficacy of the experimental ECCS-50 therapy. ECCS-50…

Researchers at UCL-Medical School in the United Kingdom recently reported in the journal PLoS One findings supporting a mechanism that leads to skin fibrosis in systemic sclerosis patients. The study is entitled “Partially Evoked Epithelial-Mesenchymal Transition (EMT) Is Associated with Increased TGFβ Signaling…

In a recent study presented during the European League Against Rheumatism Annual European Congress of Rheumatology, patients with gastrointestinal symptoms associated with systemic sclerosis may benefit from IV immunoglobulin therapy treatment. For the study, Raja J. and colleagues recruited 15 patients with a diagnosis of systemic sclerosis (SSc) from the…

A collaboration between Bristol-Myers Squibb Company and The Medical University of South Carolina (MUSC) will focus on translational research for developing scleroderma and other fibrotic disease treatments. The goal is to combine the two teams’ expertise to advance exciting new research into effective therapeutic options for patients with fibrotic disease.

Patients in the LOTUSS study who were treated for systemic sclerosis-associated idiopathic pulmonary fibrosis (SSc-IPF) using Esbriet (pirfenidone) showed signs of drug tolerability, according to a presentation at the European League Against Rheumatism (EULAR) 2015 congress held in Rome. Esbriet, which was approved by the Food and…